Table 1.

Reported randomised controlled trials (RCTs) in patients with OAC, highlighting equivalent overall survival following chemotherapy only or multimodal regimens, despite higher pathological complete response (pCR) rates and negative resection (R0) margins with multimodal therapy.

Trial	Comparison	Overall survival arm A	Overall survival arm B	R0	pCR
POET [37] (n = 119)	Arm A: CF/w x 14 versus Arm B: Same + 30 Gy+ CEt	24% 5 years	40% 5 years, P = 0.0055	79% versus 88% 41/52 versus 43/49	2% versus 12% (1/59 versus 7/60), P = 0.03
AUSTRALIAN [35] (n = 75)	Arm A: CF/q21d x2 versus Arm B: Same + 35 Gy	36% 5 years	45% 5 years	88% versus 100% 29/33 versus 33/33	0 versus 13% (0/36 versus 5/39), P = 0.05
NEORES I [36] (n = 181) 72% Adeno	Arm A: CF/q21d x 3 versus Arm B: Same + 40 Gy	49% 3 years	47% 3 years	74% versus 87% 58/78 versus 68/78, P = 0.042	8% versus 24% (7/91 versus 22/90), P = 0.002

C cisplatin, F fluorouracil, Et etoposide, E epirubicin.